Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
Y134
Catalog No. T23540Cas No. 849662-80-2
Y134 is an estrogen receptor inhibitor that is selective and orally active, exhibiting strong antagonist activity against ERα and Erβ with Ki of 0.09 nM and 11.31 nM, respectively. The selectivity of Y134 for ERα is 121.1 times higher than that for ERβ. Y134 inhibited the proliferation of ER positive human breast cancer cells stimulated by estrogen.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $151 | In Stock | |
| 5 mg | $348 | In Stock | |
| 10 mg | $498 | In Stock | |
| 25 mg | $812 | In Stock | |
| 50 mg | $1,130 | In Stock | |
| 100 mg | $1,520 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Y134"
Estropipate
T03457280-37-7
Estropipate (Piperazine estrone sulfate) is a natural estrogenic substance composed of estrone sulfate and piperazine.
- $41
Size
QTY
Estrogen receptor antagonist 8
T786462889370-92-5In house
Estrogen receptor antagonist 8 acts as an estrogen receptor (ER) antagonist with anti-uterine activity and potential anti-tumorigenic activity and can be used to study ovarian dysfunction.
- $293
Size
QTY
ET receptor antagonist 2
T79574
ET Receptor Antagonist 2 (Compound 16j) is an orally active ET receptor antagonist with an IC50 of 0.22 nM, suitable for pulmonary arterial hypertension (PAH) research. It has been shown to mitigate monocrotaline-induced PAH in a rat model [1].
- Inquiry Price
Size
QTY
4-hydroxyestrone-4-methyl ether
T945558562-33-7
4-hydroxyestrone-4-methyl ether (4-Methoxy Estrone) is the methylation of 4-OHE1, which is catalyzed by COMT.
- $115
Size
QTY
Amcenestrant
T128322114339-57-8
Amcenestrant (SAR439859) is an orally active, nonsteroidal and selective degrader of estrogen receptor (SERD). SAR439859 is a potent antagonist of ER (with an EC50 of 0.2 nM for ERα degradation).
- $147
Size
QTY
WAY-200070
T3958440122-66-7
WAY-200070 is a specific agonist of estrogen receptor β (ERRβ, IC50: 2.3 nM).
- $36
Size
QTY
G15
T73891161002-05-6
G15 is a cell-permeable non-steroidal antagonist of GPER (Ki = 20 nM)
- $33
Size
QTY
Saikosaponin D
T391320874-52-6
Saikosaponin D is a novel SERCA inhibitor by inhibiting NF-κB and STAT3 signaling to protect against acetaminophen-induced hepatotoxicity.
- $47
Size
QTY
(-)-(S)-Equol
T6491531-95-3
(-)-(S)-Equol (4',7-Dihydroxyisoflavan) is an orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.
- $43
Size
QTY
ARV-471
T397102229711-68-4
ARV-471 (Vepdegestrant) is a orally active Cereblon -based estrogen receptor (ER) PROTAC degrader. ARV-471 is developed for the research of breast cancer.
- $265
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Y134 is an estrogen receptor inhibitor that is selective and orally active, exhibiting strong antagonist activity against ERα and Erβ with Ki of 0.09 nM and 11.31 nM, respectively. The selectivity of Y134 for ERα is 121.1 times higher than that for ERβ. Y134 inhibited the proliferation of ER positive human breast cancer cells stimulated by estrogen. |
| In vitro | Y134 displays robust antagonistic effects on estrogen receptors (ERs) in CV-1 cells co-transfected with plasmids carrying ERα or ERβ along with estrogen-response element-driven luciferase, resulting in a significant decrease in luciferase activity.[1] Treatment with Y134 (0.01 nM-10 μM; 6 d) effectively suppresses the proliferation of ER-expressing breast cancer cells (MCF-7 and T47D) stimulated by estrogen.[1] |
| In vivo | Administration of Y134 (1-3 mg/kg/day; p.o. for 3 days) completely eliminates the estrogen-induced growth of terminal end buds (TEB) in the mammary glands of ovariectomized rats. Y134 exhibits a dose-dependent inhibition of uterine cell proliferation induced by estrogen (E2). [1] |
| Alias | Y 134 |
| Molecular Weight | 472.6 |
| Formula | C28H28N2O3S |
| Cas No. | 849662-80-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||
| Solubility Information | DMSO: 47.26mg/ml (90.0 mM) Ethanol: 47.26mg/ml (90.0 mM) | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.